Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AIDS-related malignancies

C Smith1, S Lilly, K P Mann

  • 1Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

Annals of Medicine
|October 23, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does primary Streptococcus viridans pneumonia exist?

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·1992
Same author

Acyl-CoA:cholesterol O-acyl transferase (ACAT) inhibitors. 1. 2-(Alkylthio)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT.

Journal of medicinal chemistry·1992
Same author

Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite.

Archives of biochemistry and biophysics·1992
Same author

Acupuncture: an ancient treatment modality under scientific scrutiny.

Journal of the American Veterinary Medical Association·1992
Same author

Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1992
Same author

Screening for alpha-thalassemia. Correlation of hemoglobin H inclusion bodies with DNA-determined genotype.

Archives of pathology & laboratory medicine·1992

This article examines various cancers that occur more frequently in people living with HIV, including lymphomas and Kaposi's sarcoma, while discussing their clinical management and therapeutic options.

Area of Science:

  • Oncology research within AIDS-related malignancies medicine
  • Clinical immunology and infectious disease studies

Background:

No prior work has fully synthesized the rising burden of oncological complications among individuals living with human immunodeficiency virus. That uncertainty drove the need to categorize specific cancer types linked to immune suppression. It was already known that a significant portion of patients diagnosed with this viral infection eventually develop malignant growths. Prior research has shown that certain conditions like Kaposi's sarcoma serve as primary indicators of disease progression. This gap motivated a comprehensive look at how prolonged survival impacts cancer prevalence. Experts have observed that standard definitions of these illnesses often exclude emerging secondary tumors. That reality necessitates a broader understanding of the diverse spectrum of neoplasms currently affecting this population. Researchers now aim to clarify the relationship between extended life expectancy and the emergence of these complex health challenges.

Purpose Of The Study:

The aim of this article is to review the clinical and therapeutic aspects of the most common cancers associated with human immunodeficiency virus. This work addresses the urgent need to understand why certain tumors occur more frequently in this patient group. The researchers seek to clarify the link between prolonged immune deficiency and the rising incidence of various malignancies. This study focuses on providing a detailed overview of both well-known and emerging cancer types. The authors intend to equip clinicians with the knowledge required to manage these complex health outcomes effectively. By examining current therapeutic options, the paper highlights the challenges inherent in treating patients with these secondary illnesses. The motivation stems from the observation that improved antiviral treatments have extended patient lifespans, thereby increasing the risk of cancer development. This review serves as a guide for medical professionals to navigate the evolving landscape of these serious health complications.

Keywords:
HIV infectionKaposi's sarcomaNon-Hodgkin's lymphomaImmunodeficiency disorders

Frequently Asked Questions

The researchers propose that prolonged survival in an immunocompromised state allows for the development of various neoplasms. While non-Hodgkin's lymphoma and Kaposi's sarcoma are well-recognized, the authors note that other cancers like squamous-cell carcinoma also show increased incidence in this population.

The authors focus on non-Hodgkin's and Hodgkin's lymphomas, Kaposi's sarcoma, and anogenital epithelial neoplasias. These specific conditions are highlighted due to their clinical significance and the therapeutic challenges they present for patients with advanced immune deficiency.

Clinicians must become familiar with these conditions because effective antiviral treatments allow patients to live longer. This extended lifespan means that individuals are at a higher risk of developing secondary tumors that were previously less common in this specific patient demographic.

Related Experiment Videos

Main Methods:

The review approach involves a systematic examination of clinical and therapeutic literature regarding cancer development in immunocompromised individuals. Investigators synthesized data from various reports to identify patterns in tumor incidence among the studied cohort. This methodology focuses on comparing well-known AIDS-defining illnesses with other emerging malignant conditions. The authors evaluated existing therapeutic strategies to determine their effectiveness in managing these complex patient cases. Review approach protocols included analyzing historical trends in patient survival and the subsequent rise in secondary diagnoses. Experts scrutinized clinical guidelines to provide a comprehensive overview of current management standards. This design ensures that the findings reflect the most relevant information for practitioners in the field. The study relies on existing evidence to construct a clear picture of the current oncological landscape for this population.

Main Results:

Key findings from the literature indicate that up to 40% of patients diagnosed with this condition will eventually develop some form of cancer. The data show that non-Hodgkin's lymphoma, Kaposi's sarcoma, and invasive cervical cancer occur with significantly higher frequency in these individuals. Key findings from the literature reveal that several other malignancies, including squamous-cell carcinoma and melanoma, also demonstrate an increased incidence. The authors report that these specific tumors are classified as defining illnesses for the condition. Key findings from the literature highlight that the prevalence of these cancers is expected to climb as patients survive longer. The review notes that advanced immunodeficiency creates a unique environment for the emergence of various germ-cell tumors and plasmacytoma. Key findings from the literature suggest that clinicians must adapt to this growing clinical burden to provide adequate care. The evidence confirms that effective antiviral therapies have inadvertently contributed to the rising number of secondary cancer cases observed in recent years.

Conclusions:

The authors suggest that medical professionals must prioritize awareness regarding the spectrum of tumors associated with immune deficiency. Synthesis and implications indicate that as survival rates improve, the frequency of these conditions will likely rise. The review highlights that non-Hodgkin's lymphoma and Kaposi's sarcoma remain prominent concerns for clinicians treating these patients. Evidence implies that anogenital epithelial neoplasias require consistent monitoring to manage patient health effectively. The authors propose that therapeutic strategies must evolve to address the unique needs of individuals living longer with the virus. Synthesis and implications emphasize that early detection of these malignancies remains a priority for improving long-term outcomes. The researchers conclude that ongoing vigilance is necessary to mitigate the impact of these secondary health issues. Future clinical practice should integrate these findings to better support the aging population of patients with this chronic condition.

The researchers utilize clinical reports and epidemiological data to synthesize information on cancer incidence. This approach allows them to compare the prevalence of AIDS-defining illnesses against other emerging malignancies like melanoma and germ-cell tumors.

The authors measure the impact of the virus by tracking the incidence of specific cancers. They observe that up to 40% of patients may develop some form of cancer, contrasting this with the general population's risk profile for these specific tumors.

The authors imply that as therapeutic efficacy improves, the medical community must prepare for a higher volume of cancer cases. They suggest that current treatment protocols should be adapted to address the shifting landscape of these secondary illnesses.